Jankowski Jess's Form 4 filing
Solesence, Inc.SLSN · filed Sep 8, 2023
- Accession no.
- 0001209191-23-048852
- Filed
- Sep 8, 2023
- Trade date
- Sep 6-8, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions and 3 derivative transactions. Open-market sales total $6.00K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Jankowski JessCIK 0001184478 | Director, Officer (President, CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 6, 2023 | Common Stock | MOption exerciseAcquired | +1,000 | $0.52 | +$520 | 60,000 | Direct | |
| Sep 6, 2023 | Common Stock | SSaleDisposed | −1,000 | $1.00 | −$1,000 | 59,000 | Direct | |
| Sep 7, 2023 | Common Stock | MOption exerciseAcquired | +2,500 | $0.52 | +$1,300 | 61,500 | Direct | |
| Sep 7, 2023 | Common Stock | SSaleDisposed | −2,500 | $1.00 | −$2,500 | 59,000 | Direct | |
| Sep 8, 2023 | Common Stock | MOption exerciseAcquired | +2,500 | $0.52 | +$1,300 | 61,500 | Direct | |
| Sep 8, 2023 | Common Stock | SSaleDisposed | −2,500 | $1.00 | −$2,500 | 59,000 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 6, 2023 | Common Stock | MOption exerciseDisposed | −73,450 | $0.52 | −$520 | 72,450 | Direct | |
| Sep 7, 2023 | Common Stock | MOption exerciseDisposed | −72,450 | $0.52 | −$1,300 | 69,950 | Direct | |
| Sep 8, 2023 | Common Stock | MOption exerciseDisposed | −69,950 | $0.52 | −$1,300 | 67,450 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker to avoid the loss of these stock option rights. His goal is to have this broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Given the quantity of shares involved relative to daily trading volume, the limited amount of open trading days available due to trading blackout periods, and looming stock option expirations, Mr. Jankowski established a 10b5-1 Plan to avoid the loss of these rights in a way intended to minimize the impact on Nanophase shareholders.